Linked Life Data

12410058

Source:http://linkedlifedata.com/resource/pubmed/id/12410058

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-10-31
pubmed:abstractText
The aim of this prospective open label study was to assess the efficacy of olanzapine for motor symptoms in Huntington's disease (HD). Olanzapine was administrated to nine patients with genetically confirmed HD in increasing doses until satisfactory clinical effect or the appearance of side effects. The patients were evaluated at baseline and after 14 days of treatment using the motor scale of the Unified HD Rating Scale (UHDRS). The patients improved significantly in most subscores of the UHDRS, including fine motor tasks, although some patients needed a rather high dose (30 mg per day). No adverse effects were reported by the patents spontaneously or were observed directly by the investigator. High-dose olanzapine seems to be useful in choreatic HD patients. A double blind, placebo-controlled trial appears warranted to definitively establish the symptomatic value of olanzapine in HD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0362-5664
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
263-5
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:articleTitle
Olanzapine for Huntington's disease: an open label study.
pubmed:affiliation
Department of Neurology & Psychiatry, Hospital BHB Eggenberg, Graz, Austria. rm.bonelli@nextra.at
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial